We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Solvent Exposure Poses Health Risk for Pathology Workers

By LabMedica International staff writers
Posted on 07 Jul 2011
Pathologists and laboratory technicians who handle organic solvents such as toluene and xylene are at increased risk of developing autoimmune connective tissue diseases.

A new study showed an occupational health hazard involving solvent use and Raynaud’s phenomenon (RP). More...
Other studies overseas have shown similar solvent associations, but not with people exposed to solvents at work.

“Our study of 341 medical laboratory workers indicates they are more likely to develop a condition called Raynaud’s phenomenon, if they are exposed to solvents such as toluene or xylene. This raises concerns they could then have further serious health complications later in life,” said lead investigator Gordon Purdie, at the department of medicine, University of Otago, (Wellington, New Zealand).

Raynaud’s phenomenon is characterized by vasoconstriction, or the narrowing of blood vessels in the hands and other extremities, and is characterized by pain, color changes, and tautness or fullness of the fingers or toes. For some people it is a symptom or precursor of scleroderma, a rare connective tissue disease affecting multiple systems in the body and mainly among women.

Lab workers who worked with acetone or chlorinated solvents, combined with xylene or toluene, doubled their risk of developing RP. Risk of developing severe RP was even greater, in fact nine times.

The mainly female laboratory workers (79%) who used solvents in this study had higher rates of RP. Those who had worked with xylene or toluene doubled their risk of developing severe RP.

The study was presented at the Australian Rheumatology Association Scientific Meeting in Brisbane (QLD, Australia), which was held from May 14-17, 2011. The study also appeared online in the June 2011 issue of the Journal of Rheumatology.

Related Links:

University of Otago


Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
High-Density Lipoprotein Containing Cholesterol Assay
HDL-c direct FS
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.